Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The global scopolamine market size is calculated at US$ 469.29 in 2024, grew to US$ 496.47 million in 2025, and is projected to reach around US$ 826.19 million by 2034. The market is expanding at a CAGR of 5.79% between 2025 and 2034.
The scopolamine market is rapidly expanding because of the increasing demand for motion sickness treatment and nausea management. North America is dominated due to an increasing aging population, with neurological disorders driving the demand for scopolamine. Asia Pacific is the fastest growing due to increasing adoption of transdermal patches and increasing traveling activity, and continuously increasing clinical trials contribute to the growth of the market.
| Metric | Details |
| Market Size in 2025 | USD 496.47 Million |
| Projected Market Size in 2034 | USD 826.19 Million |
| CAGR (2025 - 2034) | 5.79% |
| Leading Region | North America |
| Market Segmentation | By Dosage Form, By Distribution Channel, By Region |
| Top Key Players | GlaxoSmithKline plc., Novartis AG, Caleb Pharmaceuticals, Inc., Perrigo Company plc., Alchem International, Phytex Australia, Baxter International Inc., Centroflora-Cms, Alkaloids of Australia, Myungmoon Pharma Co., LTD., Fine Chemicals Corporation. |
The scopolamine market is expanding rapidly due to its work blocking certain signals in the brain that cause vomiting and nausea. It also lowers the amount of fluids the stomach produces and reduces natural movements in the intestine. It is in the anticholinergic class of drugs. Treatment with scopolamine potentially improves survival and reduces clinical symptoms of toxicity and body weight loss in patients. Scopolamine is also applicable for other situations as determined by the healthcare provider.
AI Integration in the Scopolamine drives the growth of the market as AI-driven methods are integrated with advanced process performance and increasing capacity of manufacturing of Scopolamine. AI-driven technology also provides drug manufacturing systems with the capability to develop models through analysis of data without being explicitly programmed and to improve based on data. AI speeds up drug discovery, improves clinical trials, and enhances supply chains, output in higher efficiency and innovation. Leveraging artificial intelligence (AI) and machine learning (ML) has the strength to revolutionize the research and development of scopolamine by improving data analysis and prediction, leading to faster and more effective treatments.
Increasing Incidence of Motion Sickness
Women tend to experience motion sickness more frequently than men. Various factors can elevate the likelihood of motion sickness, including a history of migraines, hormonal fluctuations, genetic predispositions, and even one's mindset. Individuals who anticipate feeling ill are often the ones who do. Approximately one in three people is highly prone to motion sickness, while the rest may encounter it in extreme situations. Motion sickness can be triggered by exposure to various forms of movement, such as traveling in cars, boats, or planes; enjoying amusement park rides; skiing; or riding camels. This increased demand for scopolamine patches and tablets subsequently fuels the growth of the scopolamine market.
Major Side Effects of Scopolamine
The typical side effects of scopolamine include dry mouth, dizziness, and drowsiness. Additional effects may comprise dilated pupils, confusion, and urinary retention. Scopolamine can also lead to withdrawal symptoms, especially if patches are used for more than a few days, posing a risk that restricts the growth of the scopolamine market.
Increasing Medical Tourism
Healthcare and tourism are among the fastest-growing sectors worldwide. Medical Value Travel is emerging as a hybrid product combining these two industries. Its growth is evident globally, with many opportunities still untapped. The rise in wellness tourism attracts consumers from different points on the wellness spectrum, particularly those seeking activities and destinations that enhance their wellness lifestyle and support proactive health maintenance. The rise in surgeries and travel-related conditions in medical tourism hubs may increase the demand for antiemetics and motion sickness medications like scopolamine, presenting a chance for growth in the scopolamine market.
By dosage form, the transdermal patches segment dominated in the scopolamine market in 2024, as scopolamine transdermal patch is applied to avoid nausea and vomiting after narcotic pain medicines, anesthesia, and surgery. It acts by releasing the drug over a longer period, like weekly. Patches provide a convenient and efficient way to ensure constant drug levels in the body of patients.
The scopolamine tablets segment is expected to grow at a significant rate over the forecast period, 2025 to 2035, as scopolamine tablets belong to a group of medicines, antimuscarinics, used to prevent nausea and vomiting caused by motion sickness or medications used in surgery. These tablets also treat symptoms of irritable bowel syndrome and Parkinson's disease. This medication comes in a tablet that is taken by mouth with water.
By distribution channel, the hospital pharmacies segment held the largest share of the scopolamine market in 2024, as hospital pharmacy is the department in a hospital that is responsible for distributing, purchasing, and supplying medicines to both inpatients and outpatients. Recently, hospital pharmacy has integrated with drug monitoring services and drug information services. The hospital pharmacist can purchase, store, handle, price, and dispense medications.
The retail pharmacies segment is expected to be the fastest-growing over the forecast period, 2025 to 2035, as retail pharmacies play a significant role in medical care by offering convenient access to various drugs, a broad range of products, and valuable insight. Retail pharmacies are an important part of medical care systems and, in numerous countries, are responsible for dispensing a huge proportion of medical products and associated services.
North America is dominant in the scopolamine market with the largest revenue share. Due to the presence of advances in science and technology, the research-based pharmaceutical industry is entering an exciting, novel era in drug development in North America. The transformative medical care industry is driven by the adoption of modern drug manufacturing and discovery technology, which contributes to the growth of the market.
In the United States, increasing spending is forecast to grow 4 to 7% through 2028, lifted by new drugs and offset by expiries and price cuts. The number of manufacturing facilities in the U.S. has grown by more than 50%. The biopharmaceutical sector continues to build, expand, and advance facilities in the country to supply the next generation of modern therapies to US patients. Increasing cases of Norovirus in the U.S. It is the leading cause of vomiting and diarrhoea due to gastroenteritis, inflammation of the stomach and intestines, which increases the demand for scopolamine.
In Canada, growing investment in healthcare, such as over $7 billion annually, is invested in health research and development in this region.The Government of Canada has spent close to $200 billion over 10 years to improve health care solutions for Canadians, which contributes to the growth of the market.
The Asia Pacific region is projected to experience the fastest growth in the scopolamine market during the forecast period, due to the APAC healthcare sector having strong potential for growth and major biotech companies that drive innovation. Increasing disposable incomes are also driving medical care spending, and a rapidly growing aging population is driving the market growth. The huge increase in air travel in Asia Pacific, driven by more demand for motion sickness medicines such as scopolamine.
China is the largest healthcare-developing country with a population of over 1.4 billion. China has achieved most of the targets and has made huge achievements in encouraging health, also growing awareness of OTC medicine drives the demand of the market.
The increasing travel sector of India, driven by tech-empowered, exploratory travelers from smaller cities, ranging from resident culture to global destinations, is leading to more cases of motion sickness, which increases the demand for scopolamine. The presence of a large aging population with GI challenges, they more prone to conditions like vomiting, vertigo, and nausea; scopalmine can manage these conditions.
Europe is expected to grow significantly in the scopolamine market during the forecast period, due to the presence of outstanding research institutions, advanced leaders in clinical research, and leading healthcare systems. Growing clinical studies that evaluate advanced uses and delivery forms of scopalmine, which causes the growth of the market.
Germany is the top pharmaceutical manufacturing region. In 2022, pharmaceutical production volume reached EUR 37.4 billion, which is equal to 8.2 % year-on-year growth. The incessantly increasing demand for healthcare products makes Germany the best location for pharmaceutical production, R&D, and sales of drugs, which contributes to the growth of the market.
By Dosage Form
By Distribution Channel
By Region
June 2025
June 2025
June 2025
June 2025